A new study by an international team led by researchers at the University of California, San Francisco (UCSF), has shed light on the mechanism of action for the anticancer effects of the Haemophilus influenzae Type b (Hib) vaccine, specifically against acute lymphoblastic leukemia (ALL).
I had the privilege recently of interviewing Aaron Ciechanover, MD, DSc, one of three co-recipients of the 2004 Nobel Prize in Chemistry for pioneering research that ultimately led to targeted therapy for treatment of cancer.
The addition of neoadjuvant carboplatin to a regimen of taxane-anthracycline chemotherapy and targeted therapy substantially increased pathological complete responses in patients with stage II/III triple-negative breast cancer (but not in patients with HER2-positive disease), according to findings of the randomized phase II GeparSixto study conducted by the German Breast Group.
Therapeutic targeting of CD24 may enhance the efﬁcacy of targeted agents, such as trastuzumab and lapatinib, in treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to a team of researchers led by Mari Hosonaga, MD, of the Department of Breast Oncology, Tokyo Medical University Hospital, Japan.
Overall Survival Extended by Adding Bevacizumab or Cetuximab to Standard Chemo Regimens in Patients With Metastatic Colorectal Cancer & No KRAS Mutations
The use of bevacizumab or cetuximab, in combination with either the FOLFOX (leucovorin/5-fluorouracil/ oxaliplatin) or FOLFIRI (leucovorin/5-fluoruracil/irinotecan) chemotherapy regimen, achieved similarly effective overall survival (OS)
CHICAGO—Addition of the immunomodulatory agent lenalidomide to R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) may reduce the negative prognostic significance of the non-GCB (germinal center B-cell) phenotyp
Interim Phase III COMBI-d Results Show PFS Benefit in Patients With BRAF V600E/K Mutant Metastatic Melanoma
CHICAGO— Interim results of the ongoing phase III COMBI-d study reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) show that patients with BRAF V600E/K mutant metastatic melanoma had a signifi
Long-term results from a phase I study demonstrate that concurrent treatment with ipilimumab and nivolumab led to an unprecedented improvement in survival for patients with advanced melanoma.
CHICAGO--In light of encouraging data from a phase II trial reported at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), the National Cancer Institute (NCI) plans to conduct two phase III clinical tr